|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cisplatin and etoposide regimen is superior to cyclophosphamide,epirubicin,and vincristine regimen in small-cell lung cancer:results from a randomized phase III trial with 5 years' follow-up显示文摘 | Sundstrom S Bremnes RM Kaasa S | | 0，，24： | 1 |
| 2 | Team - based Re- wards : Current Empirical Evidence and Directions for Future Research 显示文摘 | DEMATTEO J S EBY L T SUNDSTROM E | 1998 | Research in Organizational Behavior1998，20，： | 1 |
| 3 | Prognostic value of histological features in diffuse astrocytomas WHO grade II 显示文摘 | Lind-Landstrom T Habberstad AH Sundstrom S | 2012 | Int J Clin Exp Pathal2012，5，： | 1 |
| 4 | Carbonic anhydrase Ⅸ, hypoxia-inducible factor-lalpha, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate cox survival models following data reduction by principal component analysis of the clinicopathological predictors 显示文摘 | Korkeila EA Sundstrom J Pyrhonen S | 2011 | Anticaneer Res2011，31，12： | 1 |
| 5 | Large- scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease 显示文摘 | GANNA A SALIHOVIC S SUNDSTROM J | 2014 | PLoS Genet2014，10，10： | 1 |
| 6 | Multicenter phase Ⅱ trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited - stage small - cell lung cancer显示文摘 | Bremnes RM Sundstrom S Vilsvit J | 2001 | J Clin Oncol2001，19，： | 1 |
| 7 | Prospective study of hu- man papillomavirus ( HPV ) types, HPV persistence, and risk of squamous cell carcinoma of the cervix 显示文摘 | Sundstrom K Eloranta S Sparon P | 2010 | Cancer Epidemiol Bio- markers Prev2010，19，10： | 1 |
| 8 | Fouling of electrodialysis membranes by organic substances显示文摘 | Sundstrom G Jonsson A S | 2000 | Desalination2000，128，： | 1 |
| 9 | Fractionated irradiation and late changes in rat parotid gland:effects on the number of acinar cells,potassium efflux,and amylase secretion显示文摘 | Franzen L Gustafsson H Sundstrom S | 1993 | Int J Radiat Biol1993，64，1： | 1 |
| 10 | The value of prognostic factors in small-cell lung cancer:results from a randomised multicenter study with minimum 5 year follow-up显示文摘 | Bremnes R M Sundstrom S Aasebo U | 2003 | Lung Cancer2003，39，3： | 1 |
| 11 | Head injury mortality in the Nordic countries 显示文摘 | Sundstrom T Sollid S Wentzel-Larsen T | 2007 | J Neurotrauma2007，24，1： | 1 |
| 12 | Succinate receptor GPR91,a Gαi coupled receptor that increases intracellular calcium concentrations through PLCβ显示文摘 | Sundstrom L Greasley PJ Engberg S | | 0，，15： | 1 |
| 13 | Second-line chemotherapy in recurrent small cell lung cancer:results from a crossover schedule after primary treatment mt h cisplatinand etoposide(EP-regimen)or cyclophosphamide,epirubicin and vlncristin(CEV-regimen)显示文摘 | Sundstrom s Bremnes RM Kaasa S | 2005 | Lung Cancer2005，48，2： | 1 |
| 14 | Fouling of electrodialysis membranes by organic substances显示文摘 | Lindstrand V Sundstrom G Jonsson A S | 2000 | Desalination2000，128，1： | 1 |
| 15 | The value of prognostic factors in small cell lung cancer:results from a randomised multicenter study with minimum 5 year follow-up显示文摘 | Bremnes RM Sundstrom S Aasebo U | 2003 | Lung Cancer2003，39，3： | 1 |
| 16 | Cisplatin and etoposide regimen is superior to eyclophosphamide,epirubicin, and vincristine regimen in small cell lung cancer: results from a randomized phase Ⅲ trial with 5 years' follow - up 显示文摘 | Sundstrom S Bremnes RM Kaasa S | 2002 | J Clin Oncol2002，20，： | 1 |
| 17 | Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment显示文摘 | Sorcnstyn JB Sundstrom S Perell K | 2007 | J Thorac Oncol2007，2，2： | 1 |
| 18 | Cisplatin and etoposide regimen is superior to cyclophosphamide, eqirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase Ⅲ trial with 5 years'follow-up显示文摘 | Sundstrom S Bremnes RM Kaasa S | 2002 | J Clin Oncol2002，20，24： | 1 |
| 19 | Cisplatin and etoposide regimen Is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase IIl trial with 5 years'follow-Up 显示文摘 | Sundstrom S | 2002 | Journal of clinical oncology2002，20，24： | 1 |
| 20 | Cisplatln and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up显示文摘 | Sundstrom S Bremnes R M Kaasa S | 2002 | J Clin Oncol2002，20，24： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员